View by Specialty

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

Retina/Vitreous News

SPONSORED CONTENT
Save
SPONSORED CONTENT
August 28, 2024
2 min read
Save

Deep-learning model based on retinal images may help assess cardiovascular disease risk

Deep-learning model based on retinal images may help assess cardiovascular disease risk

The retinal image-based, deep-learning cardiac BioAge model accurately stratified individuals by traditional cardiovascular disease risk biomarkers, with leukocyte telomere length inversely related to BioAge score, researchers reported.

SPONSORED CONTENT
August 28, 2024
1 min read
Save

Participant visits complete in phase 2b trial of CLS-AX for wet AMD

Participant visits complete in phase 2b trial of CLS-AX for wet AMD

Clearside Biomedical announced the completion of the final participant visit in its ODYSSEY phase 2b clinical trial of CLS-AX, an axitinib injectable suspension for neovascular age-related macular degeneration.

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

SPONSORED CONTENT
August 27, 2024
1 min read
Save

Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema

Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema

AiViva Biopharma announced that it has completed enrollment and dosing of the last patient in a phase 1 clinical trial of AIV007 for wet age-related macular degeneration and diabetic macular edema.

SPONSORED CONTENT
August 25, 2024
1 min watch
Save

VIDEO: Eye6 smart glasses improve vision in patients with AMD

VIDEO: Eye6 smart glasses improve vision in patients with AMD

CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Kelley Sheets of Eyedaptic gives an overview of the Eye6 wearable vision aid for patients with age-related macular degeneration.

SPONSORED CONTENT
August 21, 2024
1 min read
Save

FDA grants rare pediatric disease designation for Leber congenital amaurosis gene therapy

FDA grants rare pediatric disease designation for Leber congenital amaurosis gene therapy

Opus Genetics received rare pediatric disease designation from the FDA for its ocular gene therapy designed to treat patients with a form of Leber congenital amaurosis, according to a press release.

SPONSORED CONTENT
August 20, 2024
1 min read
Save

OCT, visual acuity popular benchmarks in clinical practice guidelines for DME

OCT, visual acuity popular benchmarks in clinical practice guidelines for DME

A review found that OCT and visual acuity were among the most popular benchmarks in the management of diabetic macular edema in clinical practice guidelines.

SPONSORED CONTENT
August 15, 2024
10 min watch
Save

VIDEO: ANX007 for geographic atrophy demonstrates visual acuity, photoreceptor benefits

VIDEO: ANX007 for geographic atrophy demonstrates visual acuity, photoreceptor benefits

In this Healio Video Perspective from the ASRS meeting, Eleonora M. Lad, MD, PhD, of Duke University Medical Center discusses findings from the phase 2 ARCHER trial investigating ANX007 for geographic atrophy.

SPONSORED CONTENT
August 15, 2024
1 min read
Save

Gene therapy for X-linked retinoschisis receives rare pediatric disease designation

Gene therapy for X-linked retinoschisis receives rare pediatric disease designation

The FDA granted rare pediatric disease designation to ATSN-201, a gene therapy candidate for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

SPONSORED CONTENT
August 15, 2024
1 min read
Save

Vitreoretinal fellows steadily improve peel time over course of program

Vitreoretinal fellows steadily improve peel time over course of program

Vitreoretinal surgery fellows tend to become faster at peeling over the course of their fellowship, according to a study presented at the American Society of Retina Specialists annual meeting.

SPONSORED CONTENT
August 14, 2024
4 min watch
Save

VIDEO: Rate of uveitis recurrence reduced with Yutiq at 36 months

VIDEO: Rate of uveitis recurrence reduced with Yutiq at 36 months

In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses 36-month real-world data on the Yutiq implant for the treatment of chronic noninfectious uveitis.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails